Furadonin

The exact Irbit 50 mg plain tablet has identifiable official manufacturer information and a current Georgian registration entry, but another catalogue evidence row says that certificate is suspended for absent GMP documentation. Exact EU/EEA, GB and US entries were not found, and animal use is off-label.

ISCAID reserves 4.4-5 mg/kg every 8 hours for susceptible sporadic cystitis, especially multidrug-resistant infections. A controlled canine urine study found the q8h regimen produced urinary concentrations above relevant isolate MICs, and small clinical series support a role, but robust comparative cure trials and exact-Furadonin veterinary outcomes are absent.

Short q8h canine courses were generally tolerated in recent studies, but gastrointestinal effects, hypersensitivity, hepatic or pulmonary injury and potentially serious polyneuropathy remain relevant. Renal impairment both lowers urinary efficacy and increases systemic accumulation; exact-product canine safety and reproductive data are absent.

At 4.4-5 mg/kg, one intact 50 mg tablet fits only about a 10-11.4 kg dog per dose. It is more usable than the 100 mg strength but remains a plain tablet without validated equal division or crushing, and every-8-hour dosing with food and water is burdensome.

The exact Irbit 50 mg plain tablet has identifiable official manufacturer information and a current Georgian registration entry, but another catalogue evidence row says that certificate is suspended for absent GMP documentation. Exact EU/EEA, GB and US entries were not found, and animal use is off-label.

ISCAID includes the same 4.4-5 mg/kg every-8-hour reserve regimen for dogs and cats, and canine/feline isolate MICs support potential urinary activity. Direct feline PK and controlled clinical-outcome evidence are essentially absent, bacterial cystitis is uncommon in younger cats and this exact human tablet has no feline formulation evidence.

A 2025 cat developed presumptive peripheral polyneuropathy after 4 mg/kg every 8 hours, improving after withdrawal; the case also had impaired renal indicators. Alongside gastrointestinal, hepatic, pulmonary and hypersensitivity risks, sparse feline safety data and renal dependence make the margin materially uncertain.

A typical 4 kg cat requires about 17.6-20 mg per dose, still well below one 50 mg tablet. The exact plain tablet has no validated equal subdivision or crushing method; although less mismatched than 100 mg, accurate every-8-hour home dosing generally requires an appropriate compounded or alternative presentation.

This exact Olainfarm/Olpha 100 mg plain tablet has a current Lithuanian national authorisation, regulator-hosted 2024 product documents and current manufacturer information. It is a human presentation with no dog or cat authorisation; the catalogue market rows incorrectly report no EU/EEA registration and a current Georgian status despite an expired Georgian record.

ISCAID reserves 4.4-5 mg/kg every 8 hours for susceptible sporadic cystitis, especially multidrug-resistant infections. A controlled canine urine study found the q8h regimen produced urinary concentrations above relevant isolate MICs, and small clinical series support a role, but robust comparative cure trials and exact-Furadonin veterinary outcomes are absent.

Short q8h canine courses were generally tolerated in recent studies, but gastrointestinal effects, hypersensitivity, hepatic or pulmonary injury and potentially serious polyneuropathy remain relevant. Renal impairment both lowers urinary efficacy and increases systemic accumulation; exact-product canine safety and reproductive data are absent.

At 4.4-5 mg/kg, one intact 100 mg tablet fits only about a 20-22.7 kg dog per dose. The exact tablet is plain and not documented for equal division or crushing; three daily doses with food and water impose substantial adherence burden and make most other weights impractical without a compounded or lower-strength alternative.

This exact Olainfarm/Olpha 100 mg plain tablet has a current Lithuanian national authorisation, regulator-hosted 2024 product documents and current manufacturer information. It is a human presentation with no dog or cat authorisation; the catalogue market rows incorrectly report no EU/EEA registration and a current Georgian status despite an expired Georgian record.

ISCAID includes the same 4.4-5 mg/kg every-8-hour reserve regimen for dogs and cats, and canine/feline isolate MICs support potential urinary activity. Direct feline PK and controlled clinical-outcome evidence are essentially absent, bacterial cystitis is uncommon in younger cats and this exact human tablet has no feline formulation evidence.

A 2025 cat developed presumptive peripheral polyneuropathy after 4 mg/kg every 8 hours, improving after withdrawal; the case also had impaired renal indicators. Alongside gastrointestinal, hepatic, pulmonary and hypersensitivity risks, sparse feline safety data and renal dependence make the margin materially uncertain.

A typical 4 kg cat requires about 17.6-20 mg per dose, far below one 100 mg tablet. The exact plain tablet has no validated equal subdivision or crushing method, and forcing an inaccurate fraction every 8 hours is unacceptable; use an appropriate compounded or alternative presentation if treatment is justified.